We have previously shown that tumours resistant to ICB do not gain any advantage from the combination of adagrasib and anti-PD-1, even though KRASG12C inhibition can partially reverse immune suppression mechanisms in these models24. The gene discussed is PDCD1; the disease is neoplasm.